Stock comparison
Krystal Biotech
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | KRYS | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 51C | 72B | RMD |
| Benjamin Graham | 74D | 75B | RMD |
| Philip Fisher | 74C | 75B | RMD |
| Peter Lynch | 58C | 58C | Tie |
| Joel Greenblatt | 59C | 47D | KRYS |
| Charlie Munger | 64D | 69B | RMD |
| Terry Smith | 64D | 73B | RMD |
Side-by-side metrics
| Metric | KRYS | RMD |
|---|---|---|
| Market cap | $8.83B | $30.18B |
| P/E (TTM) | 39.9x | 19.6x |
| EV/EBIT | 52.9x | 17.1x |
| ROIC (TTM) | 13.85% | 19.63% |
| Gross margin | 92.79% | 61.69% |
| Net margin | 53.92% | 27.44% |
| Revenue CAGR 5y | - | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
KRYS leads on
- Debt / Equity0.0xvs 0.1x+99%
- Net margin53.92%vs 27.44%+49%
- Gross margin92.79%vs 61.69%+34%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $8.83B+71%
- EV/EBIT17.1xvs 52.9x+68%
- P/E (TTM)19.6xvs 39.9x+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.